Floatz logo

Panobinostat

Adenomatous Polyposis Coli

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Adenomatous Polyposis Coli cohort.

Asset / SponsorPhaseRating
Sulindac
Cancer Prevention Pharmaceuticals, Inc.
Phase 3BB
Rofecoxib
Merck Sharp & Dohme LLC
Phase 4B
Rapamycin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2B
Inulin
Radboud University Medical Center
Phase 2CCC
Vsl#3 Active
Radboud University Medical Center
Phase 2CCC
Guselkumab
Janssen Research & Development, LLC
Phase 1CC
Jnj-64251330
Janssen Research & Development, LLC
Phase 1CC

Same molecule, other indications

Panobinostat is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Non-Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →